Shares of Advaxis, Inc. (NASDAQ:ADXS) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $2.74 and last traded at $2.93, with a volume of 428500 shares changing hands. The stock had previously closed at $2.97.

Several analysts have issued reports on ADXS shares. BidaskClub raised shares of Advaxis from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research note on Friday, September 15th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $19.00 price objective on shares of Advaxis in a research note on Monday, September 25th.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.27). The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. research analysts forecast that Advaxis, Inc. will post -2.21 earnings per share for the current year.

In related news, CFO Sara Bonstein sold 12,734 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,621.46. Following the transaction, the chief financial officer now owns 244,504 shares of the company’s stock, valued at $779,967.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The disclosure for this sale can be found here. Insiders have sold 1,872,291 shares of company stock worth $8,163,810 in the last three months. Insiders own 7.21% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Cutler Capital Management LLC raised its stake in Advaxis by 150.0% during the third quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 30,000 shares during the period. Stonebridge Capital Management Inc. raised its stake in Advaxis by 88.7% during the third quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 20,045 shares during the period. The Manufacturers Life Insurance Company raised its stake in Advaxis by 10.4% during the second quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 2,969 shares during the period. State Street Corp raised its stake in Advaxis by 7.8% during the second quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock worth $4,352,000 after purchasing an additional 48,485 shares during the period. Finally, DAFNA Capital Management LLC raised its stake in Advaxis by 43.6% during the second quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock worth $1,603,000 after purchasing an additional 75,000 shares during the period. 41.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Advaxis (ADXS) Reaches New 1-Year Low at $2.74” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/12/08/advaxis-adxs-reaches-new-1-year-low-at-2-74.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.